FDA Approves Carvykti™ CAR T-Cell Therapy for Relapsed/Refractory Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has approved Carvykti™ (ciltacabtagene autoleucel) CAR T-Cell therapy for relapsed/refractory multiple myeloma in adults.1,2 People must have tried at least 4 other treatments... By Editorial Team4 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Vonjo™ (pacritinib) for Intermediate- or High-Risk Myelofibrosis With Severe ThrombocytopeniaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval to Vonjo™ (pacritinib) for certain people with intermediate- or high-risk myelofibrosis. Myelofibrosis is a rare type of leukemia. It... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves Treatment for Polycythemia VeraOn November 12, 2021, the U.S. Food and Drug Administration (FDA) approved Besremi® (ropeginterferon alfa-2b-njft) injection. Besremi is approved for use by adults with polycythemia vera (PV). Besremi is not... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments2 comments
FDA Approves Scemblix for Chronic Myeloid LeukemiaPeople living with certain hard-to-treat types of chronic myeloid leukemia (CML) now have another treatment option. The U.S. Food and Drug Administration (FDA) has approved Scemblix® (asciminib), a kinase inhibitor.1-3... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments5 comments
Zynlonta Granted Accelerated Approval for Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has granted ZynlontaTM (loncastuximab tesirine-lpyl) accelerated approval to treat large B-cell lymphoma.1 Zynlonta can be used in adults with large B-cell lymphoma that... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves First Cell-Based Gene Therapy for Adults With Multiple MyelomaThe U.S. Food and Drug Administration has approved Abecma® (idecabtagene vicleucel) to treat adults with relapsed (returning) or refractory (does not respond to treatment) myeloma. Abecma is for those who... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments0 comments
Yescarta® (axicabtagene ciloleucel) Becomes First CAR T-Cell Therapy Approved for Indolent Follicular LymphomaThe U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) to treat adults with relapsed or refractory follicular lymphoma (FL) after 2 or more lines of systemic therapy... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Pepaxto® (melphalan flufenamide) Combo for Triple-Refractory MyelomaEditor’s Note: As of October 22, 2021, Pepaxto was withdrawn from the market in the United States. More information about this can be found here. The U.S. Food and Drug... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell LymphomaThe U.S. Food and Drug Administration has approved Breyanzi® (lisocabtagene maraleucel) as a new treatment for diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common type of non-Hodgkin lymphoma... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments3 comments
Ukoniq™ (umbralisib) Receives Accelerated Approval for Adults with Marginal Zone Lymphoma and Follicular LymphomaThe U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ukoniq™ (umbralisib) for certain adults with marginal zone lymphoma (MZL) and follicular lymphoma (FL).1 Umbralisib is approved for... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments1 comments
American Cancer Society Releases 2021 Report on CancerThe American Cancer Society (ACS) has released its 2021 report on cancer, called Cancer Facts and Figures 2021. The data in this report is 2 to 4 years behind the... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments3 comments
FDA Approves Xalkori® (crizotinib) for Children and Young Adults With Relapsed or Refractory, Systemic ALCLThe U.S. Food and Drug and Drug Administration (FDA) has approved a supplemental New Drug Application for Xalkori® (crizotinib). With this approval, Xalkori can be used to treat children 1... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments1 comments
New Drug APG-2575 Granted Orphan Drug Designation for the Treatment of Chronic Lymphocytic LeukemiaThe U.S. Food and Drug Administration (FDA) has granted new drug APG-2575 orphan drug designation to treat chronic lymphocytic leukemia (CLL). APG-2575 is a novel, orally administered drug that is... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments0 comments
New Drug Onureg® (azacitidine) Approved for Adults with Acute Myeloid LeukemiaThe U.S. Food and Drug Administration (FDA) has approved Onureg® (azacitidine tablets) for adults 18 years and older with acute myeloid leukemia (AML). The drug is for use in adults... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments0 comments
Darzalex® (daratumumab) Combination Approved for Adults with Relapsed or Refractory Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) in combination with carfilzomib and dexamethasone. The approved combination of drugs, known as DKd, is for adults living with... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Grants Accelerated Approval to New Drugs for Blood CancersThe U.S. Food and Drug Administration (FDA) has granted accelerated approval for 2 new drugs for the treatment of blood cancers. Blenrep (belantamab mafodotin-blmf) has been granted accelerated approval for... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments0 comments
FDA Approves Gene Therapy Tecartus For Relapsed Or Refractory Mantle Cell LymphomaThe U.S. Food and Drug Administration (FDA) has approved Tecartus for the treatment of adults with mantle cell lymphoma (MCL). Tecartus (brexucabtagene autoleucel) is a type of gene therapy. It... By Editorial Team3 min readBookmark for laterReactions 0 reactions Comments0 comments
COVID-19 Updates, July 16: Updates on People at Risk, Testing, Reopening, and a VaccineEven after months of navigating life in the COVID-19 era, keeping up with new information and news can be overwhelming. Below are some of the latest developments surrounding COVID-19 for... By Editorial Team4 min readBookmark for laterReactions 0 reactions Comments1 comments
FDA Approves Inqovi®, New Oral Treatment for Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)The U.S. Food and Drug Administration (FDA) has approved Inqovi® (decitabine and cedazuridine) tablets for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Since it... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments1 comments
Xpovio Receives Accelerated Approval for Diffuse Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has approved Xpovio for the treatment of diffuse large B-cell lymphoma. Xpovio (selinexor) is for adults with refractory or relapsed diffuse large B-cell... By Editorial Team2 min readBookmark for laterReactions 0 reactions Comments1 comments
